Solid Tumor Testing in Thailand Trends and Forecast
The future of the solid tumor testing market in Thailand looks promising with opportunities in the hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions markets. The global solid tumor testing market is expected to reach an estimated $1641.7 billion by 2031 with a CAGR of 3.5% from 2025 to 2031. The solid tumor testing market in Thailand is also forecasted to witness strong growth over the forecast period. The major drivers for this market are an increase in the utilization of supplements and steroids and an increase in unhealthy habits, such as smoking and alcohol consumption.
• Lucintel forecasts that, within the application category, melanoma is expected to witness the highest growth over the forecast period due to the growing incidence of skin tumors and related conditions globally.
• Within the end use category, the hospital is expected to witness the highest growth due to the rising incidence of tumors and chronic diseases.
Emerging Trends in the Solid Tumor Testing Market in Thailand
The solid tumor testing market in Thailand is changing rapidly due to improvements in diagnostic technologies, greater awareness of cancer, and growing interest in personalized medicine. The use of new technologies such as AI, liquid biopsy, and genomic profiling is greatly increasing the capacity of the country to effectively detect cancer at an early stage and tailor treatment options. These trends are transforming cancer management in Thailand, enhancing patient outcomes, and providing further expansion possibilities in the healthcare industry.
• Incorporation of Artificial Intelligence (AI) in Solid Tumor Detection: In Thailand, an increasing number of solid tumors are being detected using AI-based devices since such tools improve the precision and speed of diagnoses. AI analyzes medical imaging data from CT scans, MRIs, and biopsies to detect the tumor’s attributes and assist clinicians in making a speedier and more accurate diagnosis. This technology is improving, broadening, and speeding up the effective treatment of patients while reducing human errors and ineffective treatment plans. Enhanced use of AI technology in the field of oncology will improve the efficiency of cancer care throughout Thailand.
• Expansion of Liquid Biopsy Technologies: In Thailand, liquid biopsy is being adopted as a non-invasive procedure for identifying and tracking solid tumors. By capturing blood samples and searching for specific cancer biomarkers, liquid biopsy enables diagnosis of tumors, tracking of disease progression, and assessing treatment response—all from a single blood draw. The technology also has several advantages over traditional tissue biopsies, including early-stage cancer detection, relapse tracking, and mutation identification. With the growing use of liquid biopsy, cancer diagnosis and management are likely to be more precise and efficient in Thailand compared with the traditional methods focused on imaging and tissue biopsies.
• Increased Implementation of Genomic Profiling: In Thailand, genomic profiling is becoming the foundation of precision cancer therapy and is expected to continue to grow in importance. By assessing the genetic alterations of the tumors, genomic profiling allows clinicians to choose the most effective treatment options specific to the particular patient’s tumor. The overall approach reduces ineffective therapies and adverse reactions while maximizing the benefits of therapy. As more practitioners within the healthcare sector in Thailand adopt genomic profiling, it is anticipated that there will be greater demand for this technology, which will subsequently enhance the quality of cancer diagnosis and treatment outcomes.
• Expansion of Government Spending on Screening Aspects of Cancer: The Thai government has intensified funding for cancer screening initiatives, concentrating on early detection of breast, colorectal, and lung cancers. This new focus on screening is contributing to the detection of cancers at much earlier and more treatable stages. Health campaigns, together with new access to diagnostic services, are refreshing the information landscape regarding the importance of early cancer detection. These initiatives are expected to increase the demand for solid tumor testing technologies as well as improve general cancer care in the country.
• Trends in the Development of Targeted and Individualized Cancer Treatments: In Thailand, there is a growing use of targeted therapies in the cancer treatment paradigm. These therapies seek to directly target specific genetic mutations and other molecular markers present in the tumors, so they have fewer side effects than traditional treatments. The adoption of targeted therapies is growing along with the use of genomic testing because these unique treatments require detailed tumor assays. This shift is improving cancer care in Thailand by shifting towards more bespoke treatment options for patients and enhancing the long-term survivorship of patients.
The Thailand cancer solid tumor testing market is being transformed by these emerging trends. Diagnostic precision is being improved, treatment customization is being elevated, and early diagnosis is increasing. Thailand has the opportunity to increase the efficacy and efficiency of cancer care by combining advanced technologies like AI, liquid biopsy, genomic profiling, and increased government support for cancer screening. This rapid evolution will continue to improve the patient experience as well as expand the market within the country.
Recent Developments in the Solid Tumor Testing Market in Thailand
Thailand’s cancer solid tumor testing market is projected to grow because of improving diagnostic technologies, increased participation from the government, and growing cancer prevention awareness. There is an ever-growing need for accurate and timely cancer detection as well as personalized treatment options. Proactive steps taken are expected to increase the quality of cancer care, decrease treatment expenses, and improve patients’ overall well-being.
• Integrating AI to Enhance Diagnostic Accuracy: The solid tumor testing market in Thailand is experiencing significant growth following the introduction of AI-based diagnostic tools. Algorithms built with artificial intelligence are now capable of analyzing medical data for CT and MRI scans, enabling faster and more accurate tumor detection. This technology mitigates human error and increases efficiency in diagnostics. With further integration of clinical practices and artificial intelligence tools, diagnostic accuracy and treatment response times will continue to improve, leading to better patient outcomes.
• Growth of Services for Liquid Biopsy: The adoption of liquid biopsy technology in Thailand is being accelerated due to its low-cost and non-invasive method of cancer biomarker extraction from blood samples. This development enables the noninvasive detection of cancer at early stages, tracking of its progression, and the efficiency of treatment responses via noninvasive tissue biopsies. Liquid biopsy is certainly emerging as a significant component of precision cancer treatment and will be increasingly adopted by clinics and hospitals in Thailand as it is more convenient and painless for doctors and patients.
• Government Assistance in Programs for Cancer Screening and Detection: The government of Thailand has invested heavily in cancer care services intended to increase the rate of cancer detection and decrease cancer-related deaths. Federal programs are now paying attention to the most prevalent cancers like breast, colorectal, and lung cancer and have also increased the provision of screening services. This program is helping to promote the public understanding of the need for early intervention and the use of cancer diagnostic tests. With the expansion of these programs, they will further enhance the solid tumor testing industry in Thailand.
• Development of Genomic Medicine Phased Through Asia: A notable innovation in the approach to cancer treatment in Thailand is the emergence of genomic profiling. By studying the genetic structure of the tumors, clinicians can detect alterations and construct more favorable and effective treatment regimens. More and more of these patients are being taken care of using genomic profiling in Thai healthcare institutions. With the advancement of knowledge in medicine today, many patients in Thailand are already reaping the benefits of targeted therapies that are suited to their genetic makeup and, as a result, are more suitable for them.
• Enhanced Access to Targeted Treatment Options: Cambodia’s targeted cancer treatment has significantly improved. These are therapies that are customized to treat cancer using genome medicine. These therapies are more effective with fewer side effects compared to traditional methods like chemotherapy, as they zero in on particular molecular criteria in tumors. Thailand is now able to provide effective and less harmful treatment due to the incorporation of genomic testing and increasing use of personalized medicine. This approach improves cancer survival and the general well-being of a large population of patients suffering from the disease.
Innovations in the solid tumor testing marketplace in Thailand are very encouraging, especially the application of AI technologies, expansion of liquid biopsy services, enhanced government spending on cancer screening, development of genomic profiling, and the availability of targeted treatment options as important cornerstones. All these suggested movements have the potential, at least in theory, to improve cancer treatment and diagnosis in Thailand. With these changes, it is anticipated that the market for solid tumor testing will expand, which will, in turn, stimulate the advancement of cancer treatment in the country.
Strategic Growth Opportunities for Solid Tumor Testing Market in Thailand
The market for solid tumor testing in Thailand is growing due to technological advancements, heightened healthcare awareness, and increasing government interest in cancer care. This creates various growth avenues for major players in the market. These opportunities are set to enhance cancer treatment, diagnosis, and market expansion simultaneously. It appears Thailand will continue to grow as a hub for advanced solid tumor testing due to innovations in diagnostic techniques, government efforts, and the increased use of personalized medicine.
• Implementing Artificial Intelligence (AI) in Imaging and Diagnostics: The incorporation of AI in imaging and diagnostics represents one of the most promising growth avenues for Thailand’s solid tumor testing market. AI algorithms have the potential to significantly enhance the identification of abnormal structures within medical images, such as CT scans and MRIs. These images can be processed more quickly and with greater precision, resulting in the effective detection of tumors that, if left untreated, could worsen dramatically. Keeping pace with evolving AI technology represents a great opportunity for improving diagnostics in Thailand’s healthcare system and growing the market.
• Advantages of Non-Invasive Testing with Liquid Biopsy: One promising tool that could change cancer detection is the liquid biopsy, which bypasses the need for tissue biopsy procedures and is also more affordable. With liquid biopsy, cancer detection occurs through the identification of cancer biomarkers in blood samples, allowing for earlier tumor detection and monitoring of growth. This procedure is especially attractive for patients with solid tumors. In Thailand, the presence of numerous clinics and hospitals, along with the increasing demand for cancer testing, presents an opportunity to expand liquid biopsy services and improve the country’s overall cancer care. This aligns with the global shift toward precision and personalized medicine.
• Increased Availability of Government-Funded Cancer Screening Initiatives: Alongside the increased focus on early detection of solid tumors, the Thai government’s cancer screening programs have been made available through funding. Emphasizing breast, colorectal, and lung cancer enables these diagnostic initiatives to be publicly funded under government programs, which enhances early-stage cancer diagnosis among the population. By making screening technologies more accessible, the government can lessen the burden cancer complications impose on the healthcare system. Such investments are anticipated to increase the market value and subsequently improve cancer care standards across Thailand.
• Incorporating Genomic Profiling within Cancer Treatment Plans: Cancer care is adopting genomic profiling at an accelerated rate due to its ability to identify genetic mutations associated with specific tumors. In Thailand, integrating genomic profiling into solid tumor testing can facilitate personalized care strategies, increasing treatment effectiveness while minimizing adverse side effects. The growing utilization of genomic profiling among healthcare institutions in Thailand is an important growth opportunity, as it improves clinicians’ ability to tailor therapies to the specific needs of patients, leading to more effective cancer management.
• Innovative Medicine and Custom Targeted Treatment Development: Targeted treatments that focus on specific genetic mutations in cancer cells are becoming more common in Thailand. Unlike older chemotherapies, these treatments are more effective and have fewer side effects. With the increasing trend toward personalized medicine, Thailand can enhance its market position by harnessing these innovations. This growth opportunity will be fueled by advancements in genomic testing and AI technologies, as well as the increasing demand for more precise cancer therapies.
The opportunities for strategic growth in the solid tumor testing industry in Thailand range from AI diagnostics to personalized medicine. The market is expected to grow with continuous developments in liquid biopsy, genomic profiling, and targeted therapies. Additionally, government support for cancer screening presents ample opportunities to improve cancer care in the country. With government assistance, the country can increase its screening rates and enhance overall cancer care. These factors will influence the development of solid tumor testing in Thailand, positioning it globally within the healthcare industry.
Solid Tumor Testing Market in Thailand Driver and Challenges
Various factors, such as technological advancements, sociopolitical events, and the regulatory framework, are influencing this market. With new changes come new challenges, and Thailand is witnessing growth in its healthcare system. On the positive side, technology is helping to grow the industry, but on the negative side, economic and regulatory challenges are impeding the utilization of new technologies. Understanding the major driving forces and challenges gives insight into how the industry will perform in the future.
The factors responsible for driving the solid tumor testing market in Thailand include:
• New Technologies That Make Cancer Diagnosis Easier: New technologies, such as AI imaging, liquid biopsy, and genomic profiling, have revolutionized tumor testing in Thailand. These technologies facilitate quicker, more precise, and less risky processes for cancer detection. They reduce the chances of errors during diagnosis and significantly improve patient outcomes. As these technologies become more affordable, we can expect greater accessibility, leading to early diagnoses and more precise treatments, which will result in better management of cancer care in Thailand.
• Enhanced Spending on Cancer Treatment by the Government Supports the Economy: The Thai government’s funding for healthcare infrastructure, cancer care research, and screening programs has led to improved knowledge, accessibility to solid tumor testing, and public awareness of early cancer detection. Increased government incentives for screening breast, colorectal, and lung cancer are likely to escalate demand for solid tumor testing, creating significant growth opportunities in the market.
• Growing Need for Customized Treatment Plans: In Thailand, personalized medicine is expected to achieve strong growth due to genomic testing and targeted therapeutic procedures. At the same time, there is an increasing need for solid tumor testing, as more people seek efficient and non-invasive treatment options. The solid tumor testing market is growing as advanced tools, such as gene screenings, are being used alongside targeted treatments. As the demand for less invasive treatment options increases, personalized medicine will become central in Thailand.
• Increasing Life Expectancy and Growing Cancer Cases: Thailand’s growing elderly population is contributing to an increase in cancer cases, thus driving the need for solid tumor testing. As the population ages, the likelihood of developing cancer increases, creating a large pool of patients who require testing. Combined with the need for early cancer diagnosis, these factors are driving the demand for better testing techniques. This combination is propelling the solid tumor testing market, as more patients seek diagnostic care for timely treatment.
• Enhancing Acceptance and Knowledge of Healthcare: The rise in healthcare access and increased awareness of cancer risks is another critical factor driving the solid tumor testing market in Thailand. With the expansion of public health coverage and the growing availability of cancer screening services, the demand for solid tumor testing is expected to increase. Comprehensive health campaigns and training programs are raising awareness about early detection, contributing to the greater use of solid tumor testing technologies.
Challenges in the solid tumor testing market in Thailand are:
• Prohibitive Pricing of Modern Testing Technologies: One of the most significant obstacles to the growth of the solid tumor testing market in Thailand is the high cost of available technologies. Genomic profiling and AI-powered imaging are examples of advanced diagnostic technologies that face infrastructure and human capital constraints, particularly in the public healthcare sector. While these technologies hold significant promise for improving cancer treatment, much needs to be done to deploy them properly in the poorest areas of the country.
• Challenges of Regulations and Getting Approval: Thailand has barriers that impede the swift adoption of advanced technologies in the solid tumor testing market. Slow approval processes and regulatory hurdles can limit access to new clinical tools. Delays in regulatory clearance can adversely affect the market by restricting access to innovations in diagnostic and therapeutic methods related to cancer.
• Scarcity of Trained Healthcare Workers: A major challenge for the solid tumor testing market is the shortage of healthcare professionals skilled in advanced diagnostic procedures, such as genomic profiling and liquid biopsy. Thailand is lacking a significant portion of the medical workforce needed to handle and interpret complex diagnostic machines. This skills gap can significantly hinder the adoption of new technologies and, therefore, the expansion of the market.
In Thailand, the solid tumor testing market is driven by improvements in technology, government expenditure on healthcare, and the growing need for personalized medicine. However, the market also faces significant challenges, such as the high cost of services, stringent regulations, and a lack of skilled workers. By overcoming these issues, Thailand can harness the opportunities within the solid tumor testing market and improve cancer care services.
List of Solid Tumor Testing Market in Thailand Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies, solid tumor testing companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the solid tumor testing companies profiled in this report include:
• Company 1
• Company 2
• Company 3
• Company 4
• Company 5
• Company 6
• Company 7
• Company 8
• Company 9
• Company 10
Solid Tumor Testing Market in Thailand by Segment
The study includes a forecast for the solid tumor testing market in Thailand by type, application, and end use.
Solid Tumor Testing Market in Thailand by Type [Analysis by Value from 2019 to 2031]:
• Genetic Testing
• Conventional Testing
Solid Tumor Testing Market in Thailand by Application [Analysis by Value from 2019 to 2031]:
• Prostate
• Breast
• Colorectal
• Endometrial
• Lung
• Melanoma
• Others
Solid Tumor Testing Market in Thailand by End Use [Analysis by Value from 2019 to 2031]:
• Hospitals
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic Research Institutions
Features of the Solid Tumor Testing Market in Thailand
Market Size Estimates: Solid tumor testing in Thailand market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends and forecasts by various segments.
Segmentation Analysis: Solid tumor testing in Thailand market size by type, application, and end use in terms of value ($B).
Growth Opportunities: Analysis of growth opportunities in different type, application, and end use for the solid tumor testing in Thailand.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the solid tumor testing in Thailand.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
FAQ
Q1. What are the major drivers influencing the growth of the solid tumor testing market in Thailand?
Answer: The major drivers for this market are increase in the utilization of supplements and steroids and increase in unhealthy habits, such as smoking and alcohol consumption.
Q2. What are the major segments for solid tumor testing market in Thailand?
Answer: The future of the solid tumor testing market in Thailand looks promising with opportunities in the hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions markets.
Q3. Which solid tumor testing market segment in Thailand will be the largest in future?
Answer: Lucintel forecasts that melanoma is expected to witness the highest growth over the forecast period due to growing incidence of skin tumors and related conditions globally.
Q4. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 10 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the solid tumor testing market in Thailand by type (genetic testing and conventional testing), application (prostate, breast, colorectal, endometrial, lung, melanoma, and others), and end use (hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.4. What are the business risks and competitive threats in this market?
Q.5. What are the emerging trends in this market and the reasons behind them?
Q.6. What are some of the changing demands of customers in the market?
Q.7. What are the new developments in the market? Which companies are leading these developments?
Q.8. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.9. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.10. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Solid Tumor Testing Market in Thailand, Solid Tumor Testing Market in Thailand Size, Solid Tumor Testing Market in Thailand Growth, Solid Tumor Testing Market in Thailand Analysis, Solid Tumor Testing Market in Thailand Report, Solid Tumor Testing Market in Thailand Share, Solid Tumor Testing Market in Thailand Trends, Solid Tumor Testing Market in Thailand Forecast, Solid Tumor Testing Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.